Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Beijing Immupeutics Medicine Technology Limited
Beijing, Beijing Municipality ("Beijing Shi"), Chinaimmupeutics.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
The company’s lead program IPM001—an adoptive immune cell injection sensitized with multiple TAAs/TSAs—has entered Phase I clinical trials to evaluate safety, tolerability, pharmacodynamics, and preliminary efficacy in progressive or recurrent hepatocellular carcinoma. Early results are focused on safety/tolerability; efficacy data not yet published. Additional exploratory studies are ongoing or planned for high-risk post-surgical patients.
- Therapeutic areas
- Oncology
- Modalities
- mRNA vaccinesTCR bispecificsin vivo TCR-T therapiesAutoimmune cell therapy (adoptive immune cell therapy)
- Industry
- Biotech
02
Partnerships
Peking Union Medical College Hospital – clinical trial collaboration/sponsorship partner for HCC study NCT05536427.Shanghai Huashan Hospital – sponsor/collaborator on early phase HCC recurrence prevention study NCT05105815.
Beyond the preview
Go deeper on Beijing Immupeutics Medicine Technology Limited.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Beijing Immupeutics Medicine Technology Limited.